Lilly fails to persuade Medicare to pay for Alzheimer’s imaging drug

Tracy Staton

The Centers for & Medicaid Services has handed down its final decision on Eli 's Alzheimer's agent Amyvid. The final answer, after appeals from and patient groups? No. Medicare won't pay for Amyvid-aided brain scans, not outside of clinical trials.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS